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Dual targeting of EGFR and ERBB2
pathways produces a synergistic eﬀect
on cancer cell proliferation andmigration
in vitro
M. E. Gray, S. Lee, A. L. McDowell, M. Erskine, Q. T. M. Loh, O. Grice,
D. J. Argyle and G. T. Bergkvist
The Royal (Dick) School of Veterinary Studies andThe Roslin Institute, The University of Edinburgh,
Midlothian, EH25 9RG, UK
Abstract
Members of the epidermal growth factor receptor (EGFR/ERBB) gene family are frequently
dysregulated in a range of human cancers, and therapeutics targeting these proteins are in clinical
use. We hypothesized that similar pathways are involved in feline and canine tumours and that the
same drugs may be of clinical use in veterinary patients. We investigated EGFR and ERBB2 targeting
using a panel of feline and canine cell lines. EGFR and ERBB2 were targeted with siRNAs or tyrosine
kinase inhibitors (TKIs) and their eﬀect on cellular proliferation, colony formation and migration was
investigated in vitro. Here we report that EGFR and ERBB2 combined siRNA targeting produced
synergistic eﬀects in feline and canine cell lines similar to that reported in human cell lines. We
conclude that dual EGFR and ERBB2 targeting using TKIs should be further evaluated as a potential
new therapeutic strategy in feline head and neck and mammary tumours and canine mammary
tumours.
Keywords
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Introduction
In humans, amplification or overexpression of the
oncogenes epidermal growth factor receptors 1
and 2 (EGFR and ERBB2/HER2) is associated with
the development and progression of certain types
of aggressive breast cancer, head and neck cancer
(HNSCC), ovarian, stomach and uterine cancer.
They are receptor tyrosine kinases and members
of the erythroblastic leukaemia viral oncogene
homolog (ERBB/EGFR) gene family. This family
consists of four members: EGFR/ERBB1, ERBB2,
ERBB3 and ERBB4,1 and are involved in a range of
normal cellular processes including migration, sur-
vival, proliferation, and cell cycle progression.2 The
receptors are expressed in a wide range of epithelial
and neuronal tissues.3 Gene knockout studies have
demonstrated that the gene family is crucial during
development, as homozygous null mice die during
early to mid-gestation due to multiple defects in
epithelial organ development.3,4
EGFR and ERBB2 have been reported to be
amplified in a number of human, canine and feline
cancers.5 EGFR has been reported to be overex-
pressed in feline mammary carcinomas (FMC)6,7
and oral squamous cell carcinomas (FOSCC).8,9
We have previously shown that knockdown of
EGFR in FOSCC has an additive effect when used
in combination with radiation.10 EGFR has been
reported to be both a positive9 and negative8,11
prognostic factor in FOSCC and increased expres-
sion was associated with decreased overall survival
in FMC.12 Feline mammary carcinomas have also
been reported to have an increase in tumourigenic-
ity with increased EGFR expression.6
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In canine cancers EGFR overexpression has
been reported in canine mammary tumours
(CMT),13–15 transitional cell carcinomas,16,17
medullary thyroid cancer,18 and gastric epithe-
lial tumours.19 Gama and colleagues20 reported
EGFR expression to be significantly associated with
malignancy but could only report a trend towards
reduced disease-free and overall survival. A more
recent paper using enzyme-linked immunosorbent
assay (ELISA) to detect EGFR levels in canine
mammary tumours reported a statistically signif-
icant association between high EGFR levels and
decreased disease-free and overall survival times.21
Epidermal growth factor (EGF, the principal ligand
of EGFR) was reported to stimulate proliferation,
migration, angiogenesis, and survival in canine
mammary carcinoma cell lines,22 while a correla-
tion was reported between EGFR and microvessel
density in samples from malignant CMT23 sug-
gesting the EGFR pathways might be involved
in stimulation of angiogenesis. Kennedy et al.22
demonstrated that vascular endothelial growth
factor (VEGF) production by a CMT cell line was
stimulated by the addition of EGF and blocked by
vandetanib (ZD6474), a tyrosine kinase inhibitor
(TKI) that targets VEGF receptor 2 (VEGFR-2),
EGFR and rearranged during transfection (RET)
tyrosine kinases.
Investigations into ERBB2 expression levels
have mainly been focused around FMC24–26 and
CMT.27,28 A wide range of expression percentages
have been reported following the use of multiple
techniques and different interpretations. ERBB2
plays a role in normal development of mam-
mary tissue,29 with its overexpression reported
to increase the tumour metastatic potential in
human breast cancer (HBC),30 as well as predicting
response to HER2 targeting drug trastuzumab. In
humans, targeting of EGFR in HNSCC and HER2
in HBC is well established. Drugs such as small
molecule tyrosine kinase inhibitors (TKIs) that
block the ATP binding pocket of the receptor31 or
monoclonal antibodies (mAbs) that bind directly
to the receptors on the cancer cell surface blocking
ligand binding and also potentially mediate an
antibody-dependent cellular cytotoxicity (ADCC)
or antibody-dependent cell mediated phagocytosis
(ADCP) effects32 have been of value in a subgroup
of patients where the tumours are dependent on
the EGFR pathway. The use of these drug classes
are still in their infancy in veterinary medicine.
The overall aim of this study was to investigate
the potential for EGFR and ERBB2 targeting in
veterinary medicine using a panel of feline and
canine cell lines. EGFR and ERBB2 were targeted
with siRNAs or TKIs, and their effect on cellular
proliferation, colony formation and migration
was investigated. Potential synergistic effects of
dual targeting of the receptors was investigated
in accordance to the Bliss Additivism model.33
Here we report that EGFR and ERBB2 combined
targeting by siRNAs produced a synergistic effect.
We conclude that dual targeting of EGFR and
ERBB2 should be further evaluated as a potential
new therapeutic strategy in feline and canine head
and neck and mammary tumours.
Materials andmethods
Cell culture and reagents
Cell culture reagents were obtained from Gibco
Thermo Fischer Scientific (Paisley, UK) unless oth-
erwise specified. The SCCF1 cell line is a previ-
ously characterised feline cell line derived from a
laryngeal squamous cell carcinoma and was a gift
from Professor T.J. Rosol, Ohio State University,
USA.34 The feline SCCF-SMG cell line was isolated
from a bone-invasive FOSCC, and has been charac-
terised in our laboratory (unpublished data). Both
were grown inWilliam’s EMediumwithGlutaMAX
supplemented with 10% fetal bovine serum (FBS),
0.05mg/mL gentamicin and 10 ng/mL EGF.
The CatMC35 (feline mammary adenocarci-
noma) and REM13436 (REM, canine mammary
adenocarcinoma) cell lines were previously char-
acterised and generously gifted by Professor R.
Else, R(D)SVS, The University of Edinburgh, UK.
The LILLY cell line (also from a canine mammary
tumour) was generously provided by Dr R. De
Maria, Department of Animal Pathology, Uni-
versity of Torino, Italy and was derived from a
grade three simple carcinoma from a 13-year-old
mixed breed entire female. These cell lines were
cultured in Dulbecco’s modified Eagle’s medium
(DMEM) with added GlutaMAX, supplemented
with 10% FBS and 5mL of 100 μl/mL penicillin and
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streptomycin. The media was changed and the cells
washed with phosphate buffered saline (PBS) every
48 h until confluent. Once confluent, cells were
re-seeded by washing with PBS and adding 3mL of
Trypsin-EDTA 0.25% to T75 flasks and incubated
until detachment. The human breast cancer cell
lines SK-BR-3 and BT474 cell lines were both pur-
chased fromATCC, USA and cultured as above and
according to manufacturer’s recommendations.
RNA interference
A previously published and validated siRNA
against feline EGFR (GenBank accession numbers
HQ185236.1 and KR811314.1)10 was validated
for the use in dog cells together with new siR-
NAs designed against a feline ERBB2 sequence we
previously obtained and published on GenBank
(accession number: KC710349.1). Multiple siRNA
sequences against ERBB2 were designed using a
combination of online design tools including the
siDESIGN Centre (Thermo Scientific, 2013) and
i-Score designer (i-score web service programme,
2009). Potential siRNAs were evaluated for GC
content and Reynolds scores were obtained.37
BLAST searches were then performed for selected
siRNAs against the feline whole genome sequence
(wgs) and nucleotide collection.38 The selected
siRNAs were constructed using Ambion Silencer®
siRNA Construction Kit (Life Technologies™,
Thermo Scientific) with DNA oligonucleotide
templates purchased from eurofins MWG Operon
(eurofinsdna.com, Ebersberg, Germany). Com-
mercially available negative (Silencer® Negative
control number 1, Life Technologies) and posi-
tive [glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) siRNA ON-TARGET™ plus GAPDH
Control Pool, Life Technologies,Thermo Scientific]
control siRNAs were purchased. The positive and
negative controls had been previously validated for
use in the dog and cat (data not shown).
Transfections
Cells were seeded into 96 or 6 well plates at
1.5× 103 or 1–2× 105 cells per well, respectively
in their respective media containing no antibiotics.
The cells were incubated overnight to reach approx-
imately 30–50% confluence the following day when
they were transfected according to manufacturer’s
protocol using Lipofectamine RNAiMAX™ and
OptiMEM® I Reduced-Serum media (both from
Life Technologies, Thermo Scientific) using indi-
vidual concentrations of siRNAs of 60 nM. When
a siRNA cocktail was used in the dual transfection
experiments, each siRNA was used at an individual
concentration of 20 nM. These concentrations
were selected following multiple optimisation
steps using quantitative polymerase chain reaction
(qPCR) and western blot analysis.
Protein detection
Cells were lysed in urea lysis buffer (7M urea,
0.1M DTT, 0.05% Triton X-100, 25mM NaCl,
and 20mM Hepes pH 7.5). Equal amounts of pro-
tein were separated by sodium dodecyl sulphate
(SDS) polyacrylamide gel electrophoresis and
transferred to Amersham Hybond-C nitrocellulose
membrane (GE Healthcare, Buckinghamshire,
UK) and hybridised to an appropriate primary
antibody and HRP-conjugated secondary antibody
for subsequent detection by enhanced chemilu-
minescence (ECL). Nitrocellulose membranes
were ink stained in Ponceau S solution for visu-
alisation of protein bands and conformation of
equal loading. Non-specific antibody binding was
blocked by incubating the membranes in PBS
Tween (PBST) with 5% milk (PBST/5% milk) for
1 h at room temperature. When probing for phos-
phorylated proteins the blocking solution had 1%
1M 𝛽-glycerophosphate added to it. Primary anti-
bodies against pEGFR (mouse phospho ab24918),
pERBB2 (rabbit phospho Y877) and 𝛽-actin
(mouse ab6276) were purchased from Abcam®
(Cambridge, UK), EGFR (mouse ab-12 cocktail
R19/48) from Thermo Fisher Scientific, GAPDH
(mouse 6C5, CB1001) from Merck Millipore
(Hertfordshire, UK), and c-erbB2 (rabbit A0485)
from DakoCytomation (Glostrup, Denmark). Sec-
ondary HRP-conjugated antibodies were rabbit
anti-mouse IgG and swine anti-rabbit IgG obtained
from DakoCytomation (Glostrup, Denmark). The
antibody dilutions, incubation times and tem-
peratures for the different antibodies are shown
in Table 1. Membranes were stripped for reprob-
ing using Restore™ Plus Western Blot Stripping
© 2016 The Authors. Veterinary and Comparative Oncology published by John Wiley & Sons Ltd, Veterinary and Comparative Oncology, doi: 10.1111/vco.12230
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Table 1. Summary of antibody dilutions, incubation times and conditions used for western blot analysis
Antibody Raised in species Dilution Incubation time
Anti-EGFR Mouse 1:50 Overnight at 4 ∘C
Anti-EGFR (phospho) Mouse 1:200 4–5 h at room temperature or overnight at 4 ∘C
Anti-ERBB2 Rabbit 1:1000 3–4 h at room temperature or overnight at 4 ∘C
Anti-ERBB2 (phospho) Rabbit 1:500 3–4 h at room temperature or overnight at 4 ∘C
Anti-GAPDH Mouse 1:1000 1 h at room temperature
Anti-𝛽 actin Mouse 1:10,000 1 h at room temperature
Anti-mouse Rabbit 1:1000 1 h at room temperature
Anti-rabbit Swine 1:1000 1 h at room temperature
Buffer (Thermo Fisher Scientific) according to
manufacturer’s recommendations.
Immunocytochemistry
Cells were seeded into chamber slides at a density
of 3–5× 104 cells per well in a total of 200 μL
media and incubated at 37 ∘C/5% CO2 for 24 h.
Cells were fixed in cold acetone and incubated
with an appropriate primary antibody (anti-EGFR
and anti-ERBB2 antibodies as listed in Table 1)
for subsequent detection. Secondary antibodies
goat anti-mouse AlexaFluro© 488 IgG, IgA, IgM
(A11011) and goat anti-rabbit AlexaFluro 568 IgG
(A10667) both from Life Technologies were incu-
bated at room temperature for 1 h in a dark, humid
chamber. Cover slips were removed, slides were
washed and mounted using anti-fade mounting
media containing DAPI (Vectorshield®, Vector
Laboratories Inc, Burlingame, CA, USA) and visu-
alized with a Leica DMLB2 microscope fitted with
a digital ORCA-ER digital camera and Lumencor
Spectraz LED light engine®.
Real-time PCR (qPCR)
All qPCR reactions were performed on the Roche
LightCycler® 480 machine following manufac-
turer’s instructions. The most stably expressed
reference genes hypoxanthine-guanine phospho-
ribosyltransferase (HPRT) and GAPDH were
selected using geNorm™ Reference Gene Selection
Kit (Primerdesign) with SYBR® green. Hydrolysis
probes and primers were individually designed,
tested and supplied by Primerdesign based on
previously published sequences (NCBI references
EGFR GenBank accession numbers: HQ185236.1
and KR811314.1, and ERBB2 GenBank accession
number KC710349.1). RNA was extracted using
RNeasy Mini Kit QIAshredder according to manu-
facturer’s protocol and first strand cDNA synthesis
was performed using Qiagen Omniscript® Reverse
Transcription Kit (both from Qiagen, Manchester,
UK).
The qPCR reactions were performed using
PerfectProbe™ detection chemistry (Primerde-
sign) on triplicate replicates from untreated, scram-
bled, EGFR and ERBB2 transfected cells according
to manufacturer’s instructions. Primers used were
EGFR sense 5′ ACTGTACCTACGGCTGTTCT 3′
and antisense 5′ CCACCACCACCACCAAGA 3′.
ERBB2 sense 5′ ACAGCACTTTCTACCGTTCA
3′ and antisense 5′ AGGGTCTGGGCAGAAGAA
3′. Cycling conditions are provided in Table 2.
Analysis of relative gene expression levels were per-
formed using crossing point (Cp) values obtained
for each target and reference gene using qbaseplus
(Biogazelle).The delta Cp value for each sample was
determined and the relative expression level of the
target gene was calculated according to previously
described methods.39
Drug treatment of cells
Three commercially available TKIs were used:
gefitinib (EGFR specific), AG825 (ERBB2/HER2
specific) and GW583340 (dual EGFR and ERBB2)
all supplied by Tocris Biosciences, Bristol, UK.
TKIs were supplied in powdered form and each
drug was separately dissolved in dimethyl sulphox-
ide (DMSO) to create stock solutions of 10mM.
Aliquots were made and stored at −20 ∘C. The
cell lines were treated with each TKI at a range of
concentrations (0.1-150 μM) as indicated.
© 2016 The Authors. Veterinary and Comparative Oncology published by John Wiley & Sons Ltd, Veterinary and Comparative Oncology, doi: 10.1111/vco.12230
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Table 2. Summary of qPCR cycling conditions
Programme name Target temperature (∘C) Ramp rate (∘C s−1) Hold Number of cycles
Pre-incubation 95 4.4 10min 1
Ampliﬁcation 95 4.4 15 s 40
50 2.2 30 s
72 4.4 15 s
Cooling 40 2.2 10 s 1
Cell proliferation assays
Cells were grown in the media as stipulated pre-
viously during all experiments, except for when
their basal proliferation rate in response to EGFwas
determined.The cells were grown in their respective
media with no serum added, and either a range of
EGF (5, 10 or 50 ng/mL) was added to the 96-well
plates for 24 h, or 50 ng/ml was added and the cells
were cultured for up to 48 h. Cells were seeded at
5× 103 cells per well and incubated at 37 ∘C/5%
CO2. Cell proliferation was assessed at 24 and 48 h
as measured by proxy by reading absorbance at
490 nm using Wallac 1420 Manager programme
(Perkin Elmer) following treatment with CellTitre
96® AQueous One Solution (Promega, Southamp-
ton, UK) according to manufacturer’s protocol.
For all other experiments, cells were seeded into
96-well plates at a density of 1.5× 103 cells per
well and incubated at 37 ∘C/5% CO2 for 24 h in
their respective media with serum. Cells were then
treated with TKIs at the indicated concentrations or
were transfected with the indicated concentrations
of siRNA. Cell proliferation was assessed at speci-
fied time points up to 96 h following drug exposure
or transfection as described above.
Colony formation assays
Twenty-four hours following transfection or drug
treatment cells were seeded into 10 cm plates at a
density of 300–500 cells per plate and incubated
at 37 ∘C/5% CO2. Plates were checked for colony
formation every 2 days. When visible colonies had
formed (approximately 5–10 days) the cells were
fixed with methanol and stained with 10% Giemsa
stain for counting. The colonies were electroni-
cally counted and photographed using the CCD
digital camera (Bio-Rad, Hemel Hempstead, UK)
(Fig. 2E).
Cellular migration assay
Cells were seeded into 6-well plates at a density of
2.0× 106 cells per well and incubated at 37 ∘C/5%
CO2 to achieve 100% confluence the following
day. A scratch assay was performed as previously
described.40 Briefly, cells were treated with indi-
cated concentrations of TKIs or 24–48 h following
siRNA transfections, as previously described, and
a scratch was made using a pipette tip. At regu-
lar time intervals phase contrast images of the cell
monolayer were captured with amonochrome digi-
tal Axiocamcamera fitted to aZeissAxiovert40CFL
(Carl Zeiss Ltd, Cambridge, UK) microscope until
the gap had been filled. The gap width was mea-
sured at 10 different points for each image and the
mean calculated for eachwell at each time point and
expressed as the relative migratory distance.
Statistical analysis
One-way ANOVA or the nonparametric equivalent
Kruskal–Wallis were used to compare differences
betweenmore than two samples. Two sample t-tests
or the nonparametric equivalent Mann–Whitney
U test were used to compare differences between
two samples. Results were considered significant
when P< 0.05. All statistical analysis was per-
formed using Minitab® 17 Statistical software
(Minitab Ltd.) and all graphs were generated using
Microsoft® Office Excel 2013 software.
Results
All tumour cell lines expressed EGFR
and ERBB2
Both the dog and cat cell lines showed an increase
in cell proliferation in response to increasing
EGF concentrations when grown in serum-free
media with EGF only. They also showed sustained
proliferation over a 48-h period when maintained
© 2016 The Authors. Veterinary and Comparative Oncology published by John Wiley & Sons Ltd, Veterinary and Comparative Oncology, doi: 10.1111/vco.12230
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in serum free media containing 50 ng/mL EGF
(data not show). All five cell lines expressed the
two proteins at various levels as seen using western
blot analysis (Fig. 1A). The two canine mammary
tumour cell lines (REM and LILLY) only had faint
bands present in the western blots, and when nor-
malized to the 𝛽-actin controls (Fig. 1B) the LILLY
cell line (both proteins) and REM cell line (EGFR
only) had comparatively the lowest expression
levels. To confirm protein expression immunocyto-
chemistry was performed and compared with the
feline SCCF1 cell line which has been previously
extensively validated.9 Immunocytochemistry
revealed that the proteins were primarily localized
to the cell membrane in the SCCF1 cell line (Fig.
S1, Supporting Information), while in the REM and
LILLY cell lines the protein expression was weaker
and predominantly throughout the cytoplasm of
the cells. To confirm expression in these cell lines
RT-PCR was performed using previously vali-
dated PCR primers10 (GenBank accession number
HQ185236.1 and KC710349.1). These produced
bands of the expected sizes as visualized by agarose
gel electrophoresis (data not shown).
The siRNAs successfully reduced mRNA
and protein levels of their targets
A range of siRNAs against both targets were pro-
duced and tested in the SCCF1 cell line. They pro-
duced variable levels of mRNA knockdown when
validated by qPCR at different siRNA concentra-
tions (20–100 nM). The siRNAs produced dose
dependent effects in the cell line (from 20% to up
to 75% reduction). The optimum concentration for
individual siRNA transfections was determined to
be 60 nM (data not shown) at 72 h following trans-
fections. The siRNAs that produced the greatest
reduction in mRNA levels of their specific targets
are shown in Fig. 1C and Table 3. Reduction of
EGFR and ERBB2 protein levels were confirmed
using western blot analysis in both cat (Fig. 1D–F)
and dog cells (Fig. 1E).
Targeting EGFR caused anti-proliferative
effects, reduced colony formation
and migratory ability in vitro
To initially validate the effect of EGFR and ERBB2
silencing, we used three of the cell lines (SCCF1,
CatMC and REM). Silencing of EGFR significantly
reduced cellular proliferation in all three cell lines
(P< 0.001 all three cells lines, Fig. 2A,C,D). ERBB2
silencing caused a variable response with some
reduction in cellular proliferation observed in the
CatMC cell line (P< 0.001) but no effect could
be demonstrated in the SCCF1 or REM cell lines
(Fig. 2B-D). Similarly, ERBB2 targeting produced
some reduction in colony formation ability in the
SCCF1 cell line only (P> 0.001) and no effect in the
other two cell lines, but all three cell lines responded
to EGFR targeting (Fig. 2F,G, P< 0.001, Fig. 2H,
P= 0.002). Evidence of reduced migratory ability
following EGFR, but not ERBB2 targeting was
also observed in the SCCF1 cell line (Fig. 2I–J).
It was not possible to perform scratch assays
post-transfection in the two mammary cell lines
due to their significantly reduced migration rate
compared to the SCCF1 cell line (data not shown).
Low dose dual siRNA targeting caused
synergistic effect in vitro
We then tested the effect of targeting the two recep-
tors simultaneously. The siRNA against EGFR was
so effective at the optimal dose of 60 nM that it com-
pletely blocked the cell proliferation in the cell lines
(Fig. 2), so in order to show an effect of the addition
ofERBB2wehad to reduce the concentration of siR-
NAs to a third of their optimum siRNA concentra-
tions. During the optimisation we had shown that
the siRNAs were effective at reducing the mRNA
levels in a dose responsivemanner, with 20 nM con-
centrations causing approximately 20% reduction
in mRNA levels after 24 h (data not shown). Trans-
fecting the cell with these low siRNAconcentrations
also ensured that the total siRNA concentration
used was not increased over what had been used
during optimisations and transfections with indi-
vidual siRNAs to avoid potential off target effects
due to an overall higher dose of RNA. Dual tar-
geting of both EGFR and ERBB2 using low doses
of siRNA produced a greater fractional inhibition
of cellular proliferation than individual targeting
of each receptor (Fig. 3A, P< 0.001) when com-
pared with scrambled controls. The predicted effect
of combined targeting was calculated according to
the Bliss additivism model41 and indicated that the
© 2016 The Authors. Veterinary and Comparative Oncology published by John Wiley & Sons Ltd, Veterinary and Comparative Oncology, doi: 10.1111/vco.12230
Dual EGFR and ERBB2 targeting is synergistic 7
Fi
g
u
re
1.
C
on
fir
m
at
io
n
of
EG
FR
an
d
ER
BB
2
ex
pr
es
sio
n
in
th
e
ce
ll
lin
es
an
d
va
lid
at
io
n
of
siR
N
A
s.
(A
)W
es
te
rn
bl
ot
an
al
ys
is
of
ce
ll
ly
sa
te
sf
ro
m
al
lc
el
ll
in
es
sh
ow
in
g
ex
pr
es
sio
n
of
EG
FR
(1
70
kD
a)
an
d
ER
BB
2
(1
80
kD
a)
pr
ot
ei
ns
.𝛽
-a
ct
in
(4
2
kD
a)
is
sh
ow
n
as
lo
ad
in
g
co
nt
ro
l.
(B
)I
m
ag
e
Ja
na
ly
sis
of
pr
ot
ei
n
ba
nd
sf
ro
m
th
e
w
es
te
rn
bl
ot
si
n
(A
)n
or
m
al
iz
ed
to
th
ei
rl
oa
di
ng
co
nt
ro
ls
sh
ow
re
la
tiv
e
pr
ot
ei
n
ex
pr
es
sio
n
be
tw
ee
n
th
e
ce
ll
lin
es
.(
C
)R
el
at
iv
e
ex
pr
es
sio
n
le
ve
ls
of
EG
FR
(le
ft)
an
d
ER
BB
2
(r
ig
ht
)m
RN
A
le
ve
ls
72
h
fo
llo
w
in
g
siR
N
A
tr
an
sf
ec
tio
ns
.Th
e
be
st
siR
N
A
ag
ai
ns
t
EG
FR
(E
)r
ed
uc
ed
th
e
m
RN
A
le
ve
ls
by
ap
pr
ox
im
at
el
y
75
%
co
m
pa
re
d
w
ith
sc
ra
m
bl
ed
co
nt
ro
lt
ra
ns
fe
ct
ed
(S
)a
nd
un
tr
ea
te
d
(U
)c
el
ls.
Th
e
be
st
siR
N
A
ag
ai
ns
tE
RB
B2
(E
2)
pr
od
uc
ed
ap
pr
ox
im
at
el
y
75
an
d
50
%
re
du
ct
io
n
in
m
RN
A
le
ve
ls
w
he
n
co
m
pa
re
d
w
ith
sc
ra
m
bl
ed
(S
)t
ra
ns
fe
ct
ed
an
d
un
tr
ea
te
d
(U
)c
el
ls,
re
sp
ec
tiv
el
y.
Ex
am
pl
es
sh
ow
n
is
fr
om
th
e
SC
C
F1
ce
ll
lin
e,
(−
)s
ho
w
sn
eg
at
iv
e
co
nt
ro
ls,
ba
rs
sh
ow
st
an
da
rd
er
ro
rs
of
th
e
m
ea
n.
(D
)W
es
te
rn
bl
ot
an
al
ys
is
of
pr
ot
ei
n
le
ve
ls
of
EG
FR
(le
ft)
an
d
ER
BB
2
(r
ig
ht
)7
2
h
fo
llo
w
in
g
tr
an
sf
ec
tio
n
in
th
e
SC
C
F1
ce
ll
lin
e,
(E
)i
n
th
e
C
at
M
C
ce
ll
lin
e
(b
lo
ts
to
th
e
le
ft)
an
d
RE
M
ca
ni
ne
ce
ll
lin
e
(b
lo
ts
to
th
e
ri
gh
t)
.U
,u
nt
re
at
ed
ce
lls
;M
,m
oc
k
tr
an
sf
ec
te
d
ce
lls
;S
,s
cr
am
bl
ed
co
nt
ro
lt
ra
ns
fe
ct
ed
ce
lls
;G
,G
A
PD
H
po
sit
iv
e
co
nt
ro
ls
iR
N
A
tr
an
sf
ec
te
d
ce
lls
;a
nd
E,
EG
FR
,E
2,
ER
BB
2
tr
an
sf
ec
te
d
ce
lls
.T
op
ro
w
sh
ow
sE
G
FR
or
ER
BB
2
as
in
di
ca
te
d,
ro
w
sm
ar
ke
d
G
sh
ow
po
sit
iv
e
co
nt
ro
lG
A
PD
H
(3
7
kD
a)
,a
nd
ro
w
sm
ar
ke
d
𝛽
sh
ow
𝛽
-a
ct
in
lo
ad
in
g
co
nt
ro
ls.
(F
)I
m
ag
e
Ja
na
ly
sis
of
w
es
te
rn
bl
ot
ss
ee
n
in
(D
)s
ho
w
in
g
th
e
re
du
ct
io
n
in
EG
FR
an
d
ER
BB
2
pr
ot
ei
n
le
ve
ls
w
he
n
no
rm
al
iz
ed
to
th
e
lo
ad
in
g
co
nt
ro
l.
© 2016 The Authors. Veterinary and Comparative Oncology published by John Wiley & Sons Ltd, Veterinary and Comparative Oncology, doi: 10.1111/vco.12230
8 M. E. Gray et al.
A
B
C
D
E
F
I
JG
H
Fi
g
u
re
2.
Eff
ec
to
fE
G
FR
an
d
ER
BB
2
sil
en
ci
ng
on
th
e
ce
ll
lin
es
.(
A
–D
)E
G
FR
sil
en
ci
ng
sig
ni
fic
an
tly
re
du
ce
d
pr
ol
ife
ra
tio
n
in
al
lt
hr
ee
ce
ll
lin
es
,w
hi
le
ER
BB
2
sil
en
ci
ng
ha
d
a
m
ar
gi
na
le
ffe
ct
in
th
e
C
at
M
C
ce
ll
lin
e
on
ly.
(A
)a
nd
(B
)S
C
C
F1
ce
ll
lin
e
*P
<
0.
00
1
by
on
e-
w
ay
A
N
O
VA
at
48
an
d
72
h
fo
llo
w
in
g
tr
an
sf
ec
tio
ns
.(
C
)C
at
M
C
ce
ll
lin
e,
*P
<
0.
00
1
by
on
e-
w
ay
A
N
O
VA
at
48
an
d
72
h
fo
llo
w
in
g
tr
an
sf
ec
tio
ns
.(
D
)R
EM
ce
ll
lin
e,
*P
<
0.
00
1
by
on
e-
w
ay
A
N
O
VA
at
72
h
fo
llo
w
in
g
tr
an
sf
ec
tio
ns
.(
E)
Re
pr
es
en
ta
tiv
e
im
ag
es
sh
ow
in
g
co
lo
ni
es
fo
rm
ed
in
th
e
SC
C
F1
ce
ll
lin
e
fo
llo
w
in
g
no
tr
ea
tm
en
t(
i),
sc
ra
m
bl
ed
tr
an
sf
ec
te
d
(ii
),
ER
BB
2
(ii
i)
an
d
EG
FR
(iv
)s
iR
N
A
tr
an
sf
ec
tio
ns
.(
F–
H
)C
ol
on
y
fo
rm
at
io
n
as
sa
ys
of
th
e
th
re
e
ce
ll
lin
es
:E
G
FR
kn
oc
kd
ow
n
sig
ni
fic
an
tly
re
du
ce
d
th
e
co
lo
ny
fo
rm
at
io
n
ab
ili
ty
of
th
e
ce
ll
lin
es
,w
hi
le
ER
BB
2
kn
oc
kd
ow
n
on
ly
ha
d
a
m
ar
gi
na
le
ffe
ct
in
th
e
SC
C
F1
ce
ll
lin
e,
an
d
no
de
te
ct
ab
le
eff
ec
ti
n
th
e
m
am
m
ar
y
ce
ll
lin
es
.(
F)
*P
<
0.
00
1,
(G
)*
P
<
0.
00
1,
(H
)
*P
=
0.
00
2,
by
tw
o
sa
m
pl
e
t-
te
st
.(
I)
M
ig
ra
tio
n
as
sa
ys
in
th
e
SC
C
F1
ce
ll
lin
e
fo
llo
w
in
g
siR
N
A
tr
an
sf
ec
tio
ns
.E
G
FR
sil
en
ci
ng
re
du
ce
d
th
e
re
la
tiv
e
m
ig
ra
tio
n
di
st
an
ce
w
he
re
as
ER
BB
2
ta
rg
et
in
g
ha
d
no
eff
ec
to
n
m
ig
ra
tio
n.
*P
<
0.
00
1
by
on
e-
w
ay
A
N
O
VA
(2
4
h)
an
d
K
ru
sk
al
–W
al
lis
(3
2
h)
.(
J)
Re
pr
es
en
ta
tiv
e
im
ag
es
fr
om
SC
C
F1
m
ig
ra
tio
n
as
sa
y.
A
ll
tr
an
sf
ec
tio
ns
pe
rf
or
m
ed
w
ith
siR
N
A
co
nc
en
tr
at
io
ns
of
60
nM
.E
rr
or
ba
rs
sh
ow
st
an
da
rd
de
vi
at
io
ns
.
© 2016 The Authors. Veterinary and Comparative Oncology published by John Wiley & Sons Ltd, Veterinary and Comparative Oncology, doi: 10.1111/vco.12230
Dual EGFR and ERBB2 targeting is synergistic 9
Table 3. Sequences of siRNA designed against the ERBB2 and EGFR genes
siRNA
siRNA sequence
antisense strand 5′ –3′ Target
GC
(%)
BLAST homology
(nt collection)
BLAST homology
(whole genome)
ERBB2 2 UUGACAACCCCAUUCUUGCUU ERBB2 43 14/21 18/21
EGFR 8 AGCUUCAUCAAGGAUUUCCUU EGFR 38 17/21 17/21
BA    
Figure 3. Effect on cellular proliferation when both receptors are targeted simultaneously in the SCCF1 cell line. (A) When
the cells were transfected with siRNAs at the lower concentration of 20 nM individually the effect on cell proliferation was
absent (ERBB2) or negligible (EGFR). When the two siRNAs (at 20 nM concentration each) were combined a greater
reduction in cellular proliferation was observed, *P< 0.001 by one-way ANOVA. (B) The Bliss graph shows the predicted
effect on fractional inhibition based on the fractional response to each siRNA individually. A fractional inhibition equal to
Bliss indicates additive effects and a greater fractional inhibition as demonstrated here indicates synergistic effects of dual
targeting (*).
combined targeting of EGFR and ERBB2 caused a
synergistic effect in the SCCF1 cell line (Fig. 3B).
Human TKIs blocked EGFR and ERBB2
phosphorylation in vitro
To investigate if the same effects could be achieved
by using readily available drugs we selected three
TKIs developed to block the ATP binding pockets
of the equivalent human proteins: gefitinib (specific
EGFR inhibitor), AG825 (specific HER2/ERBB2
inhibitor), and GW583340 (dual inhibitor of EGFR
and HER2/ERBB2). These were validated for use in
feline cells by performing phosphorylation assays
following serum starvation. The cells were treated
with EGF/serum with or without the TKI drugs,
and the levels of phosphorylation of the recep-
tors were determined using western blot analysis
(Fig. 4). The receptors from the feline cells became
phosphorylated in response to EGF and serum,
but if the equivalent TKI was added no change
in phosphorylation status were observed. This
is consistent with the respective TKIs blocking
phosphorylation of the human equivalent receptors
in the feline cells. This was expected, as the ATP
binding pocket of the cat and dog receptors share
a 100% amino acid sequence homology with the
human amino acid sequences and a 99% amino acid
sequence homology with the entire tyrosine kinase
domain of the receptors [GenBank Accession
numbers HQ185236.1 and AY527212.1 (EGFR),
NM_001048163.1 and NM_001003217.1 (ERBB2),
respectively]. We therefore extrapolated that the
TKIs would be effective in dog cell lines as well.
Human TKIs blocked proliferation and caused
a reduction in colony formation and migratory
ability in vitro in a panel of cell lines
Drug assays were performed in the three cell lines
to determine the relative effect of the drugs on
© 2016 The Authors. Veterinary and Comparative Oncology published by John Wiley & Sons Ltd, Veterinary and Comparative Oncology, doi: 10.1111/vco.12230
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Table 4. Approximate IC50 estimations for the cell line panel based on cell proliferation assays performed using free online
IC50 toolkit (http://www.ic50.tk/)
Cell lines
Drugs SCCF1 SCCF-SMG CatMC REM LILLY
Geﬁtinib 5.1 μM 27.7 μM 18.3 μM 28.3 μM 22.8 μM
AG825 – a – a – a – a – a
GW583340 0.6 μM 6.8 μM 1.1 μM 8.4 μM 7.5 μM
aIC50 doses for AG825 could not be determined as we could not achieve complete response to the drug at the concentration
range tested. Testing values above this range was deemed irrelevant (i.e. >50–100 μM) as such high doses equivalents would
never be achievable in vivo.
cellular proliferation (Fig. 5). Similar to what was
observed when using the siRNAs, the cell lines
were relatively more sensitive to EGFR inhibition
thanERBB2 inhibitionwhen targeting the receptors
individually. The dual inhibitor, however, reduced
cellular proliferation most effectively, with the low-
est IC50 estimated for all three cell lines (Table 4).
As these are unrelated compounds, the difference in
IC50 could also be due to difference in target affin-
ity between the compounds.The results do however
exactly mirror what was observed following siRNA
transfections targeting the receptors independently
and combined.
For comparison, two human breast cancer
cell lines with known EGFR/ERBB2 status were
also treated with the same drugs, and a similar
pattern was observed with minimal response to
ERBB2 inhibition on its own at the concentrations
0.01-10 μM, moderate reduction in cellular prolif-
eration with EGFR inhibition while dual receptor
inhibition produced the most profound effect on
cellular proliferation of all (Fig. 6).
Colony formation assays following drug treat-
ment of the cell lines showed the same pattern as
observed following siRNA transfections (Fig. 7).
EGFR blockage was effective in reducing the colony
formation ability of the cell lines whereas ERBB2
had no effect.
The migratory abilities of the cell lines were
highly variable. The two mammary carcinoma cell
lines exhibited a relatively low propensity towards
migration, even when untreated (data not shown).
After 35–48 h both untreated and DMSO control
treated cells (as shown in Fig. 8) would only on aver-
age have migrated a third to approximately half of
the distance compared with the squamous cell car-
cinoma cell linewhichwas highlymobile andwould
close the ‘wound’ in less than 24 h. The reduction
in migratory distance was therefore much easier to
assess in the latter. At 8 h the DMSO and AG825
treated SCCF1 cells would have migrated on aver-
age a quarter of the distance whereas the gefitinib
and GW583340 treated cells would have migrated
less than one tenth of the distance. After 24 h the
DMSO and AG825 treated cells had closed the
‘wound’ while the cells treated with the EGFR and
dual inhibitors would only have covered a quar-
ter of the distance (Fig. 8). A similar response was
observed in the CatMC cell line, but it was not dose
dependent. At 24 h the EGFR and dual inhibitor
treated cells had only migrated a third of the dis-
tance of the DMSO-treated cells. The REM cell line
was the least migratory of all which made assess-
ment difficult as in 35 h the DMSO-treated cells
would only have migrated approximately a third of
the distance. A slight response to ERBB2 and dual
inhibition was observed (P< 0.001), and although
this was statistically significant this is unlikely to
be biologically significant as the overall migration
of this cell line was minimal. Overall, dual tar-
geting produced similar effects as EGFR targeting
alone, and did not appear to confer any further
benefits on cellular migration in the cell line. We
then tested the effects of the TKIs on the com-
plete panel of cell lines (Fig. 9). Consistently, the
cell lines were more sensitive to EGFR targeting
(singly or in combination) and produced response
curves to the left of the ERBB2 targeting TKI.
Although the different target affinity of these com-
pounds cannot be dismissed as a potential con-
tributing factor in the effect observed, this pattern
exactly mirrored what was observed when target-
ing the receptors individually and combined using
the siRNAs.
© 2016 The Authors. Veterinary and Comparative Oncology published by John Wiley & Sons Ltd, Veterinary and Comparative Oncology, doi: 10.1111/vco.12230
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Figure 6. Dose response curves to the TKIs for the human breast cancer cell lines. (A) SK-BR-3 and (B) BT474 60 h
following treatment with gefitinib, AG825, or GW583340. Drug concentrations are given on the x-axis and the y-axis
represents percentage proliferation as compared with DMSO control treated cells. Error bars show standard deviations.
Graphs show representative results from one of a minimum of three independent experiments.
Discussion
Both the feline and the canine cell lines had the
ability to proliferate for up to 48 h when grown in
serum-free media containing EGF, and an increase
in proliferation rate was also observed in a dose
dependent manner to the addition of increasing
concentrations of EGF to the media, indicating the
cells harboured a functional EGFR pathway. All
five cell lines we tested expressed EGFR and ERBB2
but to varying degrees. Both mammary carcinomas
and oral squamous cell carcinomas are tumours
with reported overexpression of EGFR and ERBB2,
albeit with widely variable levels of overexpression
as assessed by immunohistochemistry (IHC). The
use of a standardised human test for the assess-
ment of both ERBB2 and EGFR levels (Hercept
Test™, DAKO, Glostrup, Denmark) for mammary
tumours is widely reported, although the interpre-
tation of expression levels differ. A recent paper42
sets out guidelines for how the test should be used in
canine mammary tumours when assessing ERBB2
levels with only 3+ positive tumours classed as posi-
tive.This ismore stringent than previously reported
studies where commonly 2+ and 3+ were classed
as positive. Frequently these studies would report
ERBB2 overexpression in around 30% of canine28
and 30–60% of feline12,43 mammary tumours.
Scrutinizing the data reported by Ressel et al.
(2013), a more severe interpretation using 3+ as the
cut off would reduce the positive tumours to only
3 of 35 (8.6%). In FMC Ordás et al.44 investigated
the link between the ERBB2 positive tumours and
increased gene copy numbers. In HBC, there is a
link between HER2 increased gene copy number
© 2016 The Authors. Veterinary and Comparative Oncology published by John Wiley & Sons Ltd, Veterinary and Comparative Oncology, doi: 10.1111/vco.12230
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Figure 7. Treatment with TKIs reduced the colony forming ability of the cell lines when compared to DMSO controls.
Colony formation assays of the three cell lines (A) SCCF1, (B) CatMC and (C) REM: gefitinib (at 10 μM) and GW583340 (at
4 μM) significantly reduced the colony formation ability of the cell lines when compared to DMSO controls. AG825 (at
10 μM) had no effect in any of the cell lines, (*) and (#) indicates statistically significant results: (A) *P< 0.001, (B) *P= 0.047
and #P= 0.009, (C) *P= 0.01 and #P= 0.006 by two sample t-test.
and response to trastuzumab therapy with 85–90%
of HER2 positive cases having gene amplification.42
In the Ordás’ study only 2 of 12 (16.7%) ERBB2
positive tumours showed gene amplification, and
when testing four FMC cell lines De Maria et al.24
found no gene amplification in any of them. This
may suggest that some of the reported ERBB2
positivity are either false positives or FMC ERBB2
overexpression rely on different pathways to HBC.
An even lower percentage was reported25 (5.5%)
in a study where they optimized a number of IHC
protocols despite including both 2+ and 3+ as
ERBB2 positive tumours. This study demonstrated
how much variability can be associated with pro-
cessing and interpretation. Peña et al.42 goes some
way in trying to alleviate this problem, and one of
their suggestions with respect to the Hercept Test™
is to use commercially available control slides con-
taining HBC cells of each HER2 reactivity for inter-
nal validation. As targeted therapies are starting to
become available to the veterinary patient,45 it is of
paramount importance that a robust, reliable, and
repeatable system is available for the evaluation of
expression levels. If this can be achieved, it would
prove a valuable tool for the veterinary oncologist
when choosing potential targeting therapies.
With respect to EGFR expression in mammary
tumours, less is known. It has been suggested that
FMC is a goodmodel of hormone negativeHBC,7,24
as a significant proportion of hormone negative
[oestrogen receptor (ER) and progesterone receptor
(PR)] and triple negative (ER, PR and HER2 nega-
tive) tumours express EGFR. These triple negative
HBC are associated with a very poor prognosis.
In CMT EGFR overexpression has been reported
in around 40% of malignant tumours.20,27 A func-
tional study46 treatingCMTandHBC cell lines with
humanizedmAbs against EGFR andHER2 revealed
that both antibodies blocked tumour cell prolifera-
tion by inducing growth arrest in G0/G1 phase, but
at a lower efficiency than what the same mAbs pro-
duced in the HBC cell lines. The authors suggested
that this might be due to the CMT cell lines
expressing themolecules at a 2-log lower expression
levels compared with the human cell lines.
EGFR overexpression has been reported in
FOSCC,8 and its prognostic potential has been
investigated. A small study of 22 FOSCC samples
showed an inverse relationship between EGFR
expression levels and survival,11 but a larger study
of 67 tumour samples could not verify this.9 We
have previously confirmed ERBB2 expression in
the feline cell lines by PCR and sequencing (Gen-
Bank accession number KC710349.1), ICC, and
western blot analysis. To our knowledge, no ERBB2
IHC study of FOSCC biopsy samples has been
reported.
The link between protein expression detected
using western blotting from a cell line and the levels
observed by IHC in associated tumour biopsy sam-
ples are unknown for the cell lines used in this study,
but the fact that they all seemed more sensitive to
EGFR rather than ERBB2 inhibition is interesting.
The use of receptor-specific siRNAs first confirmed
that the effect observed in the cell lines were due
to the specific knockdown of their respective recep-
tors. Despite observing a clear reduction in ERBB2
mRNA and protein levels following transfections,
© 2016 The Authors. Veterinary and Comparative Oncology published by John Wiley & Sons Ltd, Veterinary and Comparative Oncology, doi: 10.1111/vco.12230
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Figure 9. Dose response curves for the complete panel of cell lines. All cell lines tested were more sensitive to EGFR
compared to ERBB2 targeting. The feline cell lines were overall more sensitive to the TKIs than the canine cell lines were.
Graphs shown are representative results from one of triplicate experiments.
no measureable effect was observed in any of the
cell lines. ERBB2 is different to the remaining recep-
tors in its gene family in that it is incapable of ligand
binding, and hence relies on its heterodimer partner
for ligand activation.47 It is the preferred dimeri-
sation partner for all family members,47 a possible
explanation for why dual siRNA targeting caused a
synergistic effect despite minimal effect of ERBB2
monotherapy.
EGFR silencing on the other hand consistently
produced reduced cellular proliferation, colony
formation and migratory ability. The effect of dual
siRNA targeting when compared with individual
targeting suggested that a synergistic action might
be achieved when targeting the receptors simulta-
neously. A synergistic action is highly beneficial as
drugs can be given at lower doses and achieve the
same efficiency. In effect a drug that previously was
only effective at toxic doses separately may yield
the same results at subtoxic doses.33
The use of small molecule inhibitors in veteri-
nary medicine is an attractive option. The use of
toceranib48 andmasitinib49 in the treatment ofmast
cell tumours is well established. The feline, canine
and humanmRNA and amino acid sequences show
high homology for the EGFR and ERBB2 genes,
and modelling have shown great structural homol-
ogy between the canine and human proteins,46 sug-
gesting that human TKIs should be effective in
the feline and canine cells. Here we confirm using
western blot analysis that treatment of cells with
TKIs does reduce phosphorylated levels of the pro-
teins following treatment, supporting the possible
use of human TKIs in veterinary medicine. When
used in humans, tumours that initially responded
to a specific TKI were reported to develop acquired
resistance over time, and this is a great disadvan-
tage of TKIs. First generation TKIs gefitinib and
erlotinib produced overall response rates of up to
75% in patients with non-small-cell lung cancer
(NSCLC) who carried activating EGFR mutations.
Unfortunately, the median progression free sur-
vival was less than 1 year due to a secondary muta-
tion being selected for over time. The mutation
© 2016 The Authors. Veterinary and Comparative Oncology published by John Wiley & Sons Ltd, Veterinary and Comparative Oncology, doi: 10.1111/vco.12230
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responsible for 50% of these cases is the T790M
mutation in exon 20 of the human EGFR gene, but
the mechanisms for the remaining 50% of cases
are largely unproven.50 ERBB2 amplification have
been implicated as one of the mechanisms that
confer acquired resistance in NSCLC,51 which pro-
vides a rationale to target ERBB2 in combination
with EGFR.
In human medicine, monoclonal antibodies
rather than TKIs have been used in the treatment of
HBC and HNSCC (trastuzumab against HER2 and
cetuximab against EGFR, respectively). The use
of humanized mAbs in veterinary patients would
not be possible as the humanization would render
them useless because of patient immune responses
and at worst could cause adverse reactions and
anaphylaxis.45 Singer et al. reported the caniniza-
tion of a mAb against canine EGFR, and showed
its efficiency in vitro in two canine mammary cell
lines.45 This shows how personalized veterinary
oncology is becoming a distinct possibility.
Thedoses required in dogs and cats in vivo is hard
to extrapolate from in vitro studies, but some com-
parisons to human drug doses can be made. An in
vitro dose of 1 μMgefitinib is equivalent to a clinical
dose of 250mgper day used inNSCLC.52 InNSCLC
in vitro studies doses of gefitinib above 2 μMwould
class the cell line as insensitive to the drug.52 Early
studies on HNSCC cell lines used much higher
doses than this53 while more recent studies all have
used doses below 2 μM gefitinib.54,55 The cell lines
assessed in this study would therefore all be classed
as relatively insensitive to gefitinib requiring rela-
tively high doses (IC50 doses 5–28 μM). The dual
inhibitor GW583340 required a lower dose (SCCF1
and CatMC IC50 doses of 0.6 and 1.1 μM, respec-
tively), suggesting a dual inhibitor of some form
(monoclonal antibodies, RNAi or TKIs) might be
a better therapeutic option.
In summary, we have assessed the in vitro
effect of targeting the EGFR family in feline and
canine tumour cell lines from two tumour types
(oral squamous cell carcinomas and mammary
tumours) known to benefit from EGFR family
targeting in humans using RNA interference and
currently available TKIs. The benefit of TKIs over
mAbs is that they are cheaper, can be given orally,
and the human form of the drug can be utilized
without the problems associated with humanized
mAbs. It is also currently easier to achieve dual
targeting with TKIs, with several dual targeting
TKIs readily available. A caninized version of
cetuximab, however, has now been produced45 and
shown to stimulate ADCP as well as blocking the
extracellular region of the receptor. TKIs cannot
stimulate the immune response, as they act solely
by blocking the ATP-binding pocket of the recep-
tors inhibiting their phosphorylation. In addition,
acquired resistance to therapy is a commonly
reported problem encountered in human medicine
in the clinical use of TKIs.
Veterinary medicine is moving towards the pos-
sibility of offering more personalized cancer treat-
ments, and both mAbs and TKIs are likely to play
a role in this in the future. The next step requires
drugs to be identified that can be taken into con-
trolled clinical trials for further assessment of their
potential. Two things we can learn from the story so
far of targeted therapies in the human field is that
firstly, without effective patient selection the bene-
fits of targeted therapies are difficult to achieve and
secondly, that targeted therapies are rarely effective
as sole agents and should be incorporated into mul-
timodal treatment options, for example in combi-
nation with surgery, radiotherapy and established
chemotherapy protocols.Therefore it will be crucial
to establish good protocols for expression profiling
that can be used repeatedly and reliably in the vet-
erinary species.
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